Apricus Biosciences Stock Price, News & Analysis (NASDAQ:APRI)

$1.02 -0.01 (-0.97 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.02
Today's Range$1.00 - $1.06
52-Week Range$0.86 - $3.41
Volume1.18 million shs
Average Volume2.49 million shs
Market Capitalization$15.67 million
P/E RatioN/A
Dividend YieldN/A
Beta0.38

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive APRI News and Ratings via Email

Sign-up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APRI
CUSIPN/A
Phone858-222-8041

Debt

Debt-to-Equity RatioN/A
Current Ratio4.80%
Quick Ratio4.80%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.76 million
Price / Sales2.70
Cash FlowN/A
Price / CashN/A
Book Value($0.97) per share
Price / Book-1.05

Profitability

Trailing EPS$0.58
Net Income$-7,430,000.00
Net MarginsN/A
Return on Equity-527.09%
Return on Assets-126.76%

Miscellaneous

Employees15
Outstanding Shares15,220,000

Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences Inc (NASDAQ:APRI) posted its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.15. During the same period last year, the company earned ($0.19) EPS. View Apricus Biosciences' Earnings History.

When will Apricus Biosciences make its next earnings announcement?

Apricus Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Apricus Biosciences.

Where is Apricus Biosciences' stock going? Where will Apricus Biosciences' stock price be in 2018?

2 brokers have issued 1 year target prices for Apricus Biosciences' stock. Their predictions range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' share price to reach $1.00 in the next twelve months. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:

  • Kleanthis G. Xanthopoulos Ph.D., Chairman of the Board (Age 57)
  • Richard W. Pascoe, Chief Executive Officer, Principal Accounting Officer, Secretary, Director (Age 52)
  • Brian T. Dorsey, Senior Vice President, Chief Development Officer (Age 47)
  • Paul V. Maier, Independent Director (Age 69)
  • Rusty Ray, Independent Director (Age 45)
  • Sandford D. Smith, Independent Director (Age 70)
  • Wendell Wierenga Ph.D., Independent Director (Age 69)

Who owns Apricus Biosciences stock?

Apricus Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include SARISSA CAPITAL MANAGEMENT LP (13.50%), Armistice Capital LLC (5.58%) and Healthcare Value Capital LLC (0.66%). View Institutional Ownership Trends for Apricus Biosciences.

Who sold Apricus Biosciences stock? Who is selling Apricus Biosciences stock?

Apricus Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC. View Insider Buying and Selling for Apricus Biosciences.

Who bought Apricus Biosciences stock? Who is buying Apricus Biosciences stock?

Apricus Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Healthcare Value Capital LLC. View Insider Buying and Selling for Apricus Biosciences.

How do I buy Apricus Biosciences stock?

Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of Apricus Biosciences stock can currently be purchased for approximately $1.02.

How big of a company is Apricus Biosciences?

Apricus Biosciences has a market capitalization of $15.67 million and generates $5.76 million in revenue each year. The company earns $-7,430,000.00 in net income (profit) each year or $0.58 on an earnings per share basis. Apricus Biosciences employs 15 workers across the globe.

How can I contact Apricus Biosciences?

Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]


MarketBeat Community Rating for Apricus Biosciences (APRI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Apricus Biosciences (NASDAQ:APRI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.503.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.00$5.00$4.50$4.00
Price Target Upside: 68.65% downside79.86% upside166.27% upside200.75% upside

Apricus Biosciences (NASDAQ:APRI) Consensus Price Target History

Price Target History for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ:APRI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018HC WainwrightDowngradeBuy -> Neutral$1.00HighView Rating Details
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95N/AView Rating Details
3/11/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Apricus Biosciences (NASDAQ:APRI) Earnings History and Estimates Chart

Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ APRI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.15)N/AView Earnings Details
11/2/2017Q3 2017($0.15)($0.30)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.16)($0.15)ViewListenView Earnings Details
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.60)$0.30$2.53 million$5.45 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
11/12/2013Q3 2013($1.00)($0.90)$0.90 million$0.03 millionViewN/AView Earnings Details
8/14/2013Q2 2013($1.30)($1.20)$0.50 million$1.19 millionViewN/AView Earnings Details
5/10/2013Q1 2013($1.20)($2.30)$2.50 million$1.02 millionViewN/AView Earnings Details
3/18/2013Q4 2012($2.00)($2.10)ViewN/AView Earnings Details
11/8/2012Q3 2012($1.00)($0.70)ViewN/AView Earnings Details
5/10/2012Q1 2012($1.96)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.20)($2.20)ViewN/AView Earnings Details
11/14/2011Q3 2011($1.10)ViewN/AView Earnings Details
8/15/2011Q2 2011($2.54)ViewN/AView Earnings Details
5/13/2011Q1 2011($1.78)ViewN/AView Earnings Details
3/10/2011Q4 2010($1.78)ViewN/AView Earnings Details
3/31/2010Q4 2009($49.93)ViewN/AView Earnings Details
11/9/2009Q3 2009($1.95)ViewN/AView Earnings Details
8/10/2009Q2 2009($2.55)ViewN/AView Earnings Details
5/11/2009Q1 2009$1.20ViewN/AView Earnings Details
3/16/2009Q4 2008$1.50ViewN/AView Earnings Details
11/10/2008Q3 2008($5.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($3.00)$3.00ViewN/AView Earnings Details
3/12/2008Q4 2007($4.50)($6.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Apricus Biosciences (NASDAQ:APRI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.6 EPS
Next Year EPS Consensus Estimate: $-0.39 EPS

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Apricus Biosciences (NASDAQ APRI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.55%
Institutional Ownership Percentage: 24.39%
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences (NASDAQ APRI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2017Alexander J DennerMajor ShareholderBuy6,104$1.63$9,949.52View SEC Filing  
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Apricus Biosciences (NASDAQ APRI) News Headlines

Source:
DateHeadline
Apricus Biosciences (APRI) Scheduled to Post Earnings on ThursdayApricus Biosciences (APRI) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 22 at 8:16 PM
Zacks Investment Research Lowers Apricus Biosciences (APRI) to SellZacks Investment Research Lowers Apricus Biosciences (APRI) to Sell
www.americanbankingnews.com - February 22 at 4:32 PM
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call - GlobeNewswire (press release)Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:23 AM
Contrasting Apricus Biosciences (APRI) and Novartis (NVS)Contrasting Apricus Biosciences (APRI) and Novartis (NVS)
www.americanbankingnews.com - February 22 at 5:10 AM
Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in SessionApricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session
www.zacks.com - February 21 at 8:54 AM
Whats Next For Apricus Biosciences Vitaros?What's Next For Apricus Biosciences' Vitaros?
finance.yahoo.com - February 20 at 5:20 PM
Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks LikeInterested In Apricus Biosciences Inc (NASDAQ:APRI)? Here’s What Its Recent Performance Looks Like
finance.yahoo.com - February 19 at 8:28 AM
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™ - GlobeNewswire (press release)Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™ - GlobeNewswire (press release)
globenewswire.com - February 18 at 8:01 AM
Mid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet - BenzingaMid-Day Market Update: Dow Rises Over 100 Points; Apricus Biosciences Shares Plummet - Benzinga
www.benzinga.com - February 18 at 8:01 AM
Shares of Apricus tank after FDA declines to OK erectile dysfunction creamShares of Apricus tank after FDA declines to OK erectile dysfunction cream
www.reuters.com - February 17 at 8:09 AM
Apricus Biosciences (APRI) Receives CRL from FDA for VitarosApricus Biosciences (APRI) Receives CRL from FDA for Vitaros
www.streetinsider.com - February 16 at 5:22 PM
Theres No Place Like Home in BiotechThere's No Place Like Home in Biotech
finance.yahoo.com - February 16 at 5:22 PM
Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?Is It “Game Over” After Apricus Biosciences Inc (APRI) FDA Rejection?
finance.yahoo.com - February 16 at 5:22 PM
Apricus Biosciences (APRI) Downgraded by HC WainwrightApricus Biosciences (APRI) Downgraded by HC Wainwright
www.americanbankingnews.com - February 16 at 1:32 PM
FDA To Decide On APRIs ED Drug, KURA Nails It, MBRX Dynamic, GLMD Awaits ARRESTFDA To Decide On APRI's ED Drug, KURA Nails It, MBRX Dynamic, GLMD Awaits ARREST
www.nasdaq.com - February 16 at 8:12 AM
BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For VitarosBRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros
www.reuters.com - February 16 at 8:12 AM
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
finance.yahoo.com - February 16 at 8:12 AM
Apricus says FDA declines to approve erectile dysfunction creamApricus says FDA declines to approve erectile dysfunction cream
finance.yahoo.com - February 16 at 8:12 AM
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
finance.yahoo.com - February 16 at 8:12 AM
Zacks: Brokerages Anticipate Apricus Biosciences Inc (APRI) Will Post Earnings of -$0.13 Per ShareZacks: Brokerages Anticipate Apricus Biosciences Inc (APRI) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - February 9 at 12:37 PM
Another February Biotech Catalyst To Watch - Seeking AlphaAnother February Biotech Catalyst To Watch - Seeking Alpha
seekingalpha.com - February 8 at 7:01 AM
Innocoll (INNL) vs. Apricus Biosciences (APRI) Head-To-Head AnalysisInnocoll (INNL) vs. Apricus Biosciences (APRI) Head-To-Head Analysis
www.americanbankingnews.com - February 5 at 9:46 AM
Head to Head Survey: Sophiris Bio (SPHS) versus Apricus Biosciences (APRI)Head to Head Survey: Sophiris Bio (SPHS) versus Apricus Biosciences (APRI)
www.americanbankingnews.com - January 27 at 3:14 PM
Apricus Biosciences (APRI) Downgraded to Sell at Zacks Investment ResearchApricus Biosciences (APRI) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - January 23 at 5:28 PM
-$0.13 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter-$0.13 Earnings Per Share Expected for Apricus Biosciences Inc (APRI) This Quarter
www.americanbankingnews.com - January 23 at 8:56 AM
Zacks: Brokerages Anticipate Apricus Biosciences Inc (APRI) to Announce -$0.13 EPSZacks: Brokerages Anticipate Apricus Biosciences Inc (APRI) to Announce -$0.13 EPS
www.americanbankingnews.com - January 6 at 5:16 AM
Apricus Biosciences (APRI) Rating Increased to Hold at Zacks Investment ResearchApricus Biosciences (APRI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - January 3 at 5:40 PM
-$0.13 EPS Expected for Apricus Biosciences Inc (APRI) This Quarter-$0.13 EPS Expected for Apricus Biosciences Inc (APRI) This Quarter
www.americanbankingnews.com - December 20 at 7:08 PM
Head-To-Head Contrast: Lannett (LCI) vs. Apricus Biosciences (APRI)Head-To-Head Contrast: Lannett (LCI) vs. Apricus Biosciences (APRI)
www.americanbankingnews.com - December 15 at 9:32 PM
Comparing Teligent (TLGT) & Apricus Biosciences (APRI)Comparing Teligent (TLGT) & Apricus Biosciences (APRI)
www.americanbankingnews.com - December 14 at 11:04 PM
BioDelivery Sciences International (BDSI) and Apricus Biosciences (APRI) Critical AnalysisBioDelivery Sciences International (BDSI) and Apricus Biosciences (APRI) Critical Analysis
www.americanbankingnews.com - December 14 at 7:52 PM
Should You Buy Apricus Biosciences Inc (APRI) Now?Should You Buy Apricus Biosciences Inc (APRI) Now?
finance.yahoo.com - November 21 at 4:33 PM
Zacks: Analysts Expect Apricus Biosciences, Inc (APRI) to Post -$0.13 Earnings Per ShareZacks: Analysts Expect Apricus Biosciences, Inc (APRI) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - November 14 at 1:24 PM
Equities Analysts Set Expectations for Apricus Biosciences, Incs FY2017 Earnings (APRI)Equities Analysts Set Expectations for Apricus Biosciences, Inc's FY2017 Earnings (APRI)
www.americanbankingnews.com - November 10 at 8:34 AM
Zacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to SellZacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to Sell
www.americanbankingnews.com - November 7 at 9:46 PM
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30
finance.yahoo.com - November 7 at 5:42 PM
HC Wainwright Reiterates "Buy" Rating for Apricus Biosciences, Inc (APRI)HC Wainwright Reiterates "Buy" Rating for Apricus Biosciences, Inc (APRI)
www.americanbankingnews.com - November 4 at 11:32 PM
Analyzing Apricus Biosciences (APRI) and Corium International (CORI)Analyzing Apricus Biosciences (APRI) and Corium International (CORI)
www.americanbankingnews.com - November 3 at 9:14 PM
Apricus Biosciences, Inc (APRI) Posts  Earnings ResultsApricus Biosciences, Inc (APRI) Posts Earnings Results
www.americanbankingnews.com - November 3 at 8:46 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 9:22 AM
Edited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 9:22 AM
EARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q3 Earnings Report
www.rttnews.com - November 2 at 9:33 PM
Apricus reports 3Q lossApricus reports 3Q loss
finance.yahoo.com - November 2 at 9:33 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - NasdaqApricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - November 2 at 4:28 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial ResultsApricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:28 PM
Apricus Biosciences, Inc (APRI) Lifted to Buy at Zacks Investment ResearchApricus Biosciences, Inc (APRI) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 31 at 8:36 PM
Apricus Biosciences, Inc (APRI) Scheduled to Post Earnings on MondayApricus Biosciences, Inc (APRI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 3:28 AM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - GlobeNewswire (press release)Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - October 26 at 3:59 PM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - NasdaqApricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - Nasdaq
www.nasdaq.com - October 26 at 10:25 AM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference CallApricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
finance.yahoo.com - October 26 at 10:25 AM

SEC Filings

Apricus Biosciences (NASDAQ:APRI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Apricus Biosciences (NASDAQ:APRI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Apricus Biosciences (NASDAQ APRI) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.